[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2014010433A - Nueva forma cristalina de sulfato de sitagliptina. - Google Patents

Nueva forma cristalina de sulfato de sitagliptina.

Info

Publication number
MX2014010433A
MX2014010433A MX2014010433A MX2014010433A MX2014010433A MX 2014010433 A MX2014010433 A MX 2014010433A MX 2014010433 A MX2014010433 A MX 2014010433A MX 2014010433 A MX2014010433 A MX 2014010433A MX 2014010433 A MX2014010433 A MX 2014010433A
Authority
MX
Mexico
Prior art keywords
crystalline form
novel crystalline
sitagliptin sulfate
sitagliptin
sulfate
Prior art date
Application number
MX2014010433A
Other languages
English (en)
Inventor
María Del Carmen Bernabeu Martínez
Alicia Dobarro Rodríguez
Cristobal Galán Rodriguez
Original Assignee
Moehs Iberica Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moehs Iberica Sl filed Critical Moehs Iberica Sl
Publication of MX2014010433A publication Critical patent/MX2014010433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina de sulfato de sitagliptina, a un método para su obtención, a composiciones farmacéuticas que comprenden la nueva forma cristalina y a dicha forma cristalina para su uso como un medicamento.
MX2014010433A 2012-03-02 2013-03-01 Nueva forma cristalina de sulfato de sitagliptina. MX2014010433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230319A ES2421956B1 (es) 2012-03-02 2012-03-02 Nueva forma cristalina de sulfato de sitagliptina
PCT/EP2013/054164 WO2013128000A1 (en) 2012-03-02 2013-03-01 Novel crystalline form of sitagliptin sulfate

Publications (1)

Publication Number Publication Date
MX2014010433A true MX2014010433A (es) 2015-04-13

Family

ID=47754555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010433A MX2014010433A (es) 2012-03-02 2013-03-01 Nueva forma cristalina de sulfato de sitagliptina.

Country Status (14)

Country Link
US (1) US9181260B2 (es)
EP (1) EP2820019B1 (es)
AU (1) AU2013224897A1 (es)
DK (1) DK2820019T3 (es)
ES (2) ES2421956B1 (es)
HU (1) HUE033496T2 (es)
IL (1) IL234401A (es)
MX (1) MX2014010433A (es)
NZ (1) NZ629511A (es)
PL (1) PL2820019T3 (es)
PT (1) PT2820019T (es)
SI (1) SI2820019T1 (es)
WO (1) WO2013128000A1 (es)
ZA (1) ZA201406431B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
ES2792506T3 (es) 2014-02-03 2020-11-11 Galenicum Health Sl Composiciones farmacéuticas estables que contienen sitagliptina en forma de comprimidos de liberación inmediata
US20170239276A1 (en) * 2014-09-05 2017-08-24 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of sitagliptin
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AR043515A1 (es) 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
RS62595B1 (sr) 2004-01-20 2021-12-31 Novartis Ag Formulacija i proces direktne kompresije
EP1909776A2 (en) 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2009064476A1 (en) 2007-11-13 2009-05-22 Teva Pharmaceutical Industries Ltd. Preparation of sitagliptin intermediate
JP2011507890A (ja) * 2007-12-20 2011-03-10 ドクター・レディーズ・ラボラトリーズ・リミテッド シタグリプチンおよびその薬学的に許容可能な塩の調製のためのプロセス
RU2519717C2 (ru) * 2008-07-03 2014-06-20 Рациофарм Гмбх Кристаллические соли ситаглиптина
EP2218721A1 (en) 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2398803A2 (en) * 2009-03-30 2011-12-28 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
CA2800507A1 (en) * 2010-03-31 2011-10-06 Teva Pharmaceuticals Industries Ltd. Solid state forms of sitagliptin salts

Also Published As

Publication number Publication date
IL234401A (en) 2017-11-30
AU2013224897A1 (en) 2014-09-18
SI2820019T1 (sl) 2017-07-31
ES2421956A1 (es) 2013-09-06
ES2421956B1 (es) 2014-09-29
EP2820019B1 (en) 2017-03-22
PL2820019T3 (pl) 2017-09-29
US20150037406A1 (en) 2015-02-05
PT2820019T (pt) 2017-06-26
WO2013128000A1 (en) 2013-09-06
NZ629511A (en) 2016-04-29
DK2820019T3 (en) 2017-07-03
EP2820019A1 (en) 2015-01-07
HUE033496T2 (en) 2017-12-28
ZA201406431B (en) 2016-05-25
US9181260B2 (en) 2015-11-10
ES2628920T3 (es) 2017-08-04

Similar Documents

Publication Publication Date Title
IN2015KN00262A (es)
MD20150091A2 (ro) Compuşi antivirali
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
EP2736528A4 (en) COMPOSITIONS AND METHODS OF TREATING HIV
EP2702054A4 (en) NOVEL BISAMINOQUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS PREPARED THEREFROM, AND USE THEREOF
PH12018500071A1 (en) Plinabulin compositions
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
JO3154B1 (ar) عوامل مضادة لـ trpv4
EP2773342A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
IN2014DN06964A (es)
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IN2015DN00085A (es)
IN2014DN03010A (es)
IN2013MU01111A (es)
IN2014DN09451A (es)
IL245260A0 (en) Non-aqueous crystalline form of cabazitaxel, process for its preparation and pharmaceutical compositions thereof
IN2013CH04314A (es)
WO2014122671A3 (en) Solid oral compositions of saxagliptin